Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Top Cited Papers
- 26 November 2014
- journal article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 515 (7528), 572-576
- https://doi.org/10.1038/nature14001
Abstract
Human tumours typically harbour a remarkable number of somatic mutations. If presented on major histocompatibility complex class I molecules (MHCI), peptides containing these mutations could potentially be immunogenic as they should be recognized as 'non-self' neo-antigens by the adaptive immune system. Recent work has confirmed that mutant peptides can serve as T-cell epitopes. However, few mutant epitopes have been described because their discovery required the laborious screening of patient tumour-infiltrating lymphocytes for their ability to recognize antigen libraries constructed following tumour exome sequencing. We sought to simplify the discovery of immunogenic mutant peptides by characterizing their general properties. We developed an approach that combines whole-exome and transcriptome sequencing analysis with mass spectrometry to identify neo-epitopes in two widely used murine tumour models. Of the >1,300 amino acid changes identified, ∼13% were predicted to bind MHCI, a small fraction of which were confirmed by mass spectrometry. The peptides were then structurally modelled bound to MHCI. Mutations that were solvent-exposed and therefore accessible to T-cell antigen receptors were predicted to be immunogenic. Vaccination of mice confirmed the approach, with each predicted immunogenic peptide yielding therapeutically active T-cell responses. The predictions also enabled the generation of peptide-MHCI dextramers that could be used to monitor the kinetics and distribution of the anti-tumour T-cell response before and after vaccination. These findings indicate that a suitable prediction algorithm may provide an approach for the pharmacodynamic monitoring of T-cell responses as well as for the development of personalized vaccines in cancer patients.Keywords
This publication has 38 references indexed in Scilit:
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerNature Genetics, 2012
- Expression of tumour-specific antigens underlies cancer immunoeditingNature, 2012
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- Oncolytic Virus-initiated Protective Immunity Against Prostate CancerMolecular Therapy, 2011
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patientsThe Journal of Experimental Medicine, 2010
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infectionProceedings of the National Academy of Sciences of the United States of America, 2010
- Deriving the consequences of genomic variants with the Ensembl API and SNP Effect PredictorBioinformatics, 2010
- Fast and SNP-tolerant detection of complex variants and splicing in short readsBioinformatics, 2010
- NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11Nucleic Acids Research, 2008
- The MHC class I peptide repertoire is molded by the transcriptomeThe Journal of Experimental Medicine, 2008